Cleft Palate Dental denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cleft palate dental are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Cleft Palate Dental Treatment as Not FDA-Approved

Blue Cross Blue Shield may issue a not-FDA-approved denial when a device, material, or surgical technique used in cleft palate dental rehabilitation has not received FDA clearance or approval for the specific indication being treated — or when the device is being used in a manner that differs from its FDA-cleared labeling (sometimes called "off-label" use). This is distinct from an experimental denial but often accompanies one.

## Why This Denial Is Appealable

Off-label use of FDA-cleared devices and materials is legal, ethically appropriate, and extremely common in reconstructive surgery and prosthetics. FDA clearance establishes a safety and effectiveness baseline; it does not define the limits of clinically appropriate use. Professional societies in reconstructive surgery and craniofacial care regularly publish guidance supporting uses that extend beyond the original cleared indication. If the treating team can document that the use is consistent with current specialty practice, the off-label status alone does not justify denial.

## Federal Appeal Framework

• Internal appeal: ERISA §503 (employer plans) and ACA rules guarantee a full-and-fair internal appeal. File within the deadline on your denial letter — commonly 180 days.
• External review: ACA §2719 provides independent external review after internal exhaustion, within approximately four months of the final internal denial as a general guideline — confirm your exact deadline.
• Expedited review: If delay creates a serious health risk, expedited external review is available with decisions typically within 72 hours.

## Concrete Appeal Steps

1. Confirm from BCBS's denial whether the issue is (a) the device itself lacks FDA clearance, or (b) the device is FDA-cleared but being used off-label. The appeal strategy differs. 2. If off-label: obtain the treating surgeon's letter documenting the clinical rationale and citing professional society guidance that supports this use pattern. 3. If no FDA clearance: assess whether a cleared alternative exists and whether the non-cleared device was chosen for a specific, documented clinical reason. 4. Reference BCBS's own medical policy language — many BCBS policies distinguish between truly non-approved devices and off-label use of approved devices, and provide separate criteria for each.

## Documentation to Gather

• Diagnosis records confirming cleft palate diagnosis and clinical status requiring the denied device or technique
• Treating surgeon's letter explaining the specific clinical reason for the chosen device or technique and its relationship to current specialty standards
• Professional society guidance from the American Cleft Palate-Craniofacial Association or relevant surgical specialty supporting the approach
• FDA clearance documentation for the device itself (if cleared but used off-label)
• Prior treatment history showing what alternatives were considered or attempted

## Criteria-Mapping Structure

Obtain the BCBS medical policy governing the denied procedure. Identify the specific criteria used to evaluate off-label or non-approved devices — most policies list elements such as clinical evidence, specialty consensus, and the absence of a safer approved alternative. Address each element directly with the treating surgeon's documentation and applicable guideline references.